GlassScriptPhysician profile
Corina M Sandulescu
NPI 1750657490
$2,440.61
in general payments reported to CMS, 2019-2025
25 companies · $630 in 2025
The $630 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $54.55 · 2021: $46.62 · 2023: $379 · 2024: $998 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.73 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $496.88 | 2019-2025 | Evenity, Prolia |
| Astellas Pharma US INC | $248.21 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $186.76 | 2019-2025 | Myosure Tissue Removal Device, Fluent Fluid Management System, Omni Hysteroscope |
| Shield Therapeutics INC | $182.07 | 2023-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $154.64 | 2024-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $137.71 | 2019-2025 | |
| Coopersurgical, INC. | $136.10 | 2019-2025 | Paragard T 380a |
| Mayne Pharma Commercial LLC | $121.53 | 2023-2025 | |
| Pfizer INC. | $112.02 | 2023-2024 | |
| Biogen, INC. | $97.68 | 2024-2025 | Zurzuvae |
| Exact Sciences Corporation | $88.26 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $84.00 | 2019-2023 | Lo Loestrin Fe |
| Organon LLC | $75.22 | 2023-2025 | Nexplanon, Jada System |
| Exeltis, USA INC. | $67.34 | 2023-2025 | Slynd |
| Merck Sharp & Dohme LLC | $46.88 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $44.42 | 2024 | Intrarosa, Femring |
| Lupin INC. | $31.19 | 2019-2020 | |
| Radius Health, INC. | $23.54 | 2025 | Tymlos |
| Novum Pharma, LLC | $22.94 | 2019 | |
| Therapeuticsmd, INC. | $19.23 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.70 | 2025 | |
| Acessa Health INC. | $16.72 | 2019 | |
| Dysis Medical, INC. | $16.20 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.37 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corina Sandulescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.